Project
An open-label, single arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage relapsing remitting Multiple Sclerosis
Automatically Closed · 2017 until 2021
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Status
Automatically Closed
Start Date
2017
End Date
2021
Financing
Industry
Study Design
open label
Brief description/objective
Ziel der Studie ist es herauszufinden, ob Ocrelizumab (das Prüfpräparat) die Verschlechterung der
Anzeichen und Symptome Ihrer Multipler Sklerose (MS) im Frühstadium zum Stillstand bringt.